Akademik Veri Yönetim Sistemi
ONCOLOGY LETTERS, cilt.28, sa.5, ss.1-8, 2024 (SCI-Expanded)
Abstract. Soft tissue sarcomas are rare cancers and most
cases are metastatic at the time of diagnosis. Although the
chances of survival are good with surgical treatment in the
early stages, systemic treatment in the advanced stages is only
associated with a survival duration of ~12 months. Alterations
in the anaplastic lymphoma kinase (ALK) gene are becoming
increasingly recognized as pan‑cancer indicators in solid
tumors. However, little is known regarding the molecular
spectrum of ALK‑positive histiocytosis. Molecular treatments,
including ALK inhibitors, are potential treatment options. The
present case report describes an aggressive ALK‑positive
soft tissue sarcoma with intracardiac metastases and severe
leukocytosis responding to ALK inhibitors. The patient
initially responded to crizotinib but required alectinib due to
central nervous system progression. The patient has shown
a near‑complete response and remained stable for 2 years;
however, there has been recent lymph node progression